NCT07076056View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

December 4, 2023

Study Completion Date

June 19, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

DW1026C1

Sitagliptin 100mg+Empagliflozin 10mg

DRUG

DW1026C2

Sitagliptin 100mg+Empagliflozin 25mg

DRUG

DW1026S

Sitagliptin 100mg

Trial Locations (1)

Unknown

Yeouido St. Mary's Hospital The Catholic University, Seoul

Sponsors
All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY